Evidence map›Paper›PMID 41237982›Full record

ArticleNeurobiology of disease2025

The structure, redox chemistry and motor neuron toxicity of heterodimeric zinc-deficient SOD1-implications for the toxic gain of function observed in ALS.

Victor A Streltsov, Katherine E Ganio, Stewart D Nuttall, J Andres Hernandez, Cassandra N Dennys, Peter J Crouch, Alvaro G Estevez, Maria Clara Franco, Joseph S Beckman, Blaine R Roberts

Abstract read
In one paragraph

Article in Neurobiology of disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Victor A StreltsovThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia; CSIRO, Manufacturing Division, 343 Royal Parade, Parkville, Victoria 3052, Australia. Electronic address: victor.streltsov@florey.edu.au.
Katherine E GanioThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia.
Stewart D NuttallCSIRO, Manufacturing Division, 343 Royal Parade, Parkville, Victoria 3052, Australia.
J Andres HernandezBurnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32827, United States of America.
Cassandra N DennysAlcyone Therapeutics, 116 John Street, Suite 300, Lowell, MA, United States of America.
Peter J CrouchDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC 3010, Australia.
Alvaro G EstevezCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA; Departement of Cellular & Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Port St. Lucie, FL 34987, USA.
Maria Clara FrancoCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA; Departement of Cellular & Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Port St. Lucie, FL 34987, USA.
Joseph S BeckmanDepartment of Biochemistry and Biophysics, Oregon State University, Corvallis, OR 97331, USA; Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA. Electronic address: joe.beckman@oregonstate.edu.
Blaine R RobertsDepartment of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: blaine.roberts@emory.edu.

Funding

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's DiseaseR01AG070937 · NIA · EMORY UNIVERSITY · PI LAH, JAMES J · 2021 to 2025
$35.2M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Redox Signaling in NeurofibromatosisR01NS102479 · NINDS · OREGON STATE UNIVERSITY · PI FRANCO, MARIA CLARA · 2019 to 2023
$1.7M
Deciphering the IgG glycosylation code of Alzheimer's DiseaseR01AG085587 · NIA · EMORY UNIVERSITY · PI Blaine Russell Roberts, ERIC JOHN SUNDBERG · 2024 to 2026
$1.6M
Emory start-up, National Health and Medical Research Council (NHMRC) projectNIA NIH HHS R01 AG070937NIA NIH HHS R01 AG085587NIA NIH HHS U01 AG061357NINDS NIH HHS R01 NS102479
6 · The paper itself

Abstract

A subset of familial cases of amyotrophic lateral sclerosis (fALS) are caused by mutations to copper, zinc superoxide dismutase (Cu, Zn SOD1). Over 200 mutations to SOD1 that have been associated with fALS and the majority of these mutations are dominantly inherited. Thus, individuals are heterozygous and express both wild-type SOD1 and the mutant form of the protein. Paradoxically, the motor neuron disease accelerates in rodent models that mimic the co-expression of wild-type SOD1 with mutant fALS SOD1. Previously, we have shown that the loss of zinc from SOD1 triggers motor neuron death in culture due to a gained, redox activity catalyzed by the active-site copper. Furthermore, motor neuron toxicity of zinc-deficient SOD1 is enhanced by wild-type Cu, Zn SOD1. Because SOD1 exists as a non-covalent dimer, the enhanced toxicity might result from stabilization of the heterodimeric interface between zinc-deficient SOD1 and Cu, Zn-SOD1. However, experimentation with the heterodimer is difficult because SOD1 subunits exchange in minutes. To better characterize the role of dimer stabilization on the enhanced toxicity of fALS mutant SOD1 by wild type SOD1, we genetically tethered a zinc-deficient SOD1 subunit with a Cu, Zn SOD1 subunit with a 16-residue linker. The x-ray structure of the tethered heterodimer showed that the zinc-deficient subunit adopts a wild-type-like conformation and is not misfolded. The heterodimer intermediate also produced peroxynitrite from nitric oxide, and the tethered SOD1 was strikingly toxic to primary cultures of motor neurons. This work supports the concept that zinc-deficient SOD1 is a likely toxic intermediate in ALS. Furthermore, the wild-type allele in human familial-SOD1 ALS patients may physically contribute to the dominant inheritance of SOD1 mutations through heterodimer formation.

Indexed as

Amyotrophic Lateral SclerosisMotor NeuronsSuperoxide DismutaseSuperoxide Dismutase-1ZincAnimalsCells, CulturedGain of Function MutationHumansMutationOxidation-ReductionRatsSOD1 protein, humanSuperoxide DismutaseSuperoxide Dismutase-1ZincAmyotrophic lateral sclerosisProtein engineeringSuperoxide dismutase

Identifiers

PMID41237982
PMCPMC12758609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.